Diabetes: Gpr120 agonist has anti-inflammatory and insulin-sensitizing effects

Nature Reviews Endocrinology

Volumn 10, Issue 9, 2014, Pages 510-

  Greenhill, Claire ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CPDA; CYTOKINE; DOCOSAHEXAENOIC ACID; G PROTEIN COUPLED RECEPTOR 120; G PROTEIN COUPLED RECEPTOR 120 AGONIST; GLUCOSE; INSULIN; INSULIN SENSITIZING AGENT; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CYTOKINE RELEASE; DRUG EFFECT; DRUG POTENCY; GENE EXPRESSION; GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN TOLERANCE TEST; KNOCKOUT MOUSE; LIPID DIET; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, OMEGA-3; INSULIN RESISTANCE; MALE; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84906791196     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2014.118     Document Type: Note

References (1)

1. Oh, D. Y. et al. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat. Med. doi:10.1038/nm.3614